1UO FDA Approval Status

FDA Approved: No
Brand name: 1UO
Generic name: uracil
Dosage form: Topical
Previous Name: Xyfid
Company: Cahaba Pharmaceuticals
Treatment for: Hand-Foot Syndrome

1UO (uracil) is a first-in-class dihydropyrimidine dehydrogenase (DPD) inhibitor in development for the treatment of Hand-Foot Syndrome (HFS), also known as Palmar-Plantar Erythrodysesthesia.

Development timeline for 1UO

Date	Article
Sep 10, 2008	VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid
Jul 1, 2008	VioQuest Pharmaceuticals Submits 510(k) Application to FDA for Xyfid, a Novel Topical Agent for the Treatment of Various Skin Disorders

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer